CD44 as a marker in human cancers

Current Opinion in Oncology

Volumn 9, Issue 1, 1997, Pages 108-112

  Sy, Man Sun ^a   Mori, Hiroshi ^a   Liu, Dacai ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; TUMOR MARKER;

CANCER GENETICS; CELL MOTILITY; CELL SURFACE; DOWN REGULATION; HEMATOPOIESIS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SECRETORY GRANULE; SIGNAL TRANSDUCTION;

EID: 0030952304     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199701000-00017     Document Type: Review

References (57)

1. Underhill C: CD44: the hyaluronan receptor. J Cell Sci 1992, 103:293-296.
2. Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol 1993, 54:271-310.
3. Herrlich P, Zoller M, Pals ST, Ponta H: CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993, 14:395-398.
4. Laurent TC, Fraser JRE: Hyaluronan. FASEB J 1992, 6:2397-2381.
5. Toyama-Sorimachi N, Sorimachi H, Tobita Y, Kitamura F, Yagita H, Szuki K, Miyasaka M: A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. J Biol Chem 1995, 270:7437-7444.
6. Webber G, Ashkar S, Glimcher MJ, Cantor H: Receptor ligand interaction between CD44 and osteopontin (ETa-1). Science 1996, 271:509-512.
7. Stevens RL, Kamada MM, Serafin WE: Structure and function of the family of proteoglycans that reside in the secretory granules of natural killer cells and other effector cells of the immune system. Curr Top Microbiol Immunol 1988, 140:93-108.
8. Denhardt DT, Guo X: Osteopontin: a protein with diverse functions. FASEB J 1993, 7:1475-1482.
9. Underhill CB, Toole BP: Binding of hyaluronate to the surface of cultured cells. J Cell Biol 1979, 82:475-484.
10. Gunthert U, Holmann M, Rudy W, Reber S, Zoller M, Haufman I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65:13-24.
11. Hofmann U, Rudy W, Zooler M, Tolg C, Ponta H, Herrlich P, Gunthert U: CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res 1991, 51:5292-5297.
12. Heider KH, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P, Pals ST: A human homologue of the rat metastasis associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993, 120:227-233.
13. Tanabe KK, Ellis LM, Saya H: Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993, 341:725-726
14. Matsumutra Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1993, 340:1053-1058.
15. Fox SB, Gatter KC, Jackson DG, Screaton GR, Bell MV, Bell JI, Harris AL, Simmons D, Fawcett J: CD44 and cancer screening. Lancet 1993, 342:548-549.
16. Givehchian M, Woerner SM, Lacroix J, Zoller M, Drings P, Becker H, Kayser K, Ridder R, von Knebel Doeberitz M: Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogens 1996, 12:1137-1144.
17. Sy MS, Ya-Jun Guo, Stamenkovic I: Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991, 174:859-863.
18. Cooper DL, Dougherty GL: To metastasize or not? Selection of CD44 splice sites. Nat Med 1995, 1:635-637. A short and excellent article on the regulation of the expression of CD44 isoforms.
19. Sleeman J, Moll J, Sherman L, Dall P, Pals ST, Ponta H, Herrlich P: The role of CD44 splice variants in human metastatic cancer. Ciba Found Symp 1995, 189:142-151.
20. Imazeki F, Yokosuka O, Yamaguchi T, Ohto M, Isono K, Omata M: Expression of variant CD44 mRNA in colorectal adenocarcinomas and adenomatous polyps in humans. Gastroenterology 1996, 110:362-368.
21. Orzechowski HD, Beckenbach C, Herbst H, Stolezel U, Riecken EO, Stallmach A: Expression of CD44v6 is associated with cellular dysplasia in colorectal epithelial cells. Eur J Cancer 1995, 31A:2073-2079.
22. Herrlich P, Pals ST, Ponta H: CD44 in colon cancer. Eur J Cancer 1995, 31A:1110-1112.
23. Jackson PA, Green MA, Pouli A, Rubbard R, Marks CG, Cook MG: Relationship between stage, grade, proliferation and expression of p53 and CD44 in adenomas and carcinomas of the colorectum. J Clin Pathol 1995, 48:1098-1010.
24. Rodriguez C, Monges G, Rouanet P, Dutrillauz B, Lefrancois D, Thillet C: CD44 expression patterns in breast and colon tumors: a PCR based study of splice variants. Int J Cancer 1995, 54:347-354.
25. Mulder JW, Kruyt PM, Sewnath M, Seldenrijk CA, Weidema WF, Pals ST: Difference in expression of CD44 splice variants between proximal and distal adenocarcinoma of the large bowel. Br J Surg 1995, 82:1468-1470.
26. Dammrich J, Vollmers HP, Heider KH, Muller-Hermelink HK: Importance of differenct CD44v6 expression in human gastric intestinal and diffuse type cancers of metastatic lymphogenic spreading. J Mol Med 1995, 73:395-401.
27. Seelentag W, Flury R, Schmid M, Komminoth P, Saremaslani P, Gunthert U: Expression von CD44 isoformen in menschlicher normaler Leber sowie bei regererativen und neoplastischen Leberveranderungen [in German]. Verh Dtsch Ges Pathol 1995, 75:144-147.
28. Hart I, Birch M, Marshall JF: Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 1991, 10:115-130.
29. Thomas L, Byers R, Vink J, Stamenkovic I: CD44H regulates tumor cell migration on hyaluronate coated substrate. J Cell Biol 1992, 118:971-978.
30. Guo YJ, Ma J, Wang JH, Shen F, Narula M, Bigby M, Wu C, Sy SM: Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res 1994, 54:1561-1565.
31. Goebeler M, Kaufmann D, Brocker EB, Klein CE: Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci 1996, 109:1057-1964.
32. Manten-Horst E, Danen EHJ, Smit L, Snoek M, Ke Poole IC, Van Mujen GNP, Pals ST, Ruiter DJ: Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 1995, 64:182-188.
33. Prieto VG, Reed JA, McNutt NS, Bogdany JK, Lugo J, Shea CR: Differential expression of CD44 in malignant cutaneous epithelial neoplasm. Am J Dermatopathol 1995, 17:447-451.
34. Domman SN, Ziegler T, Momman-Schener CC, Meyer J, Panizzon R, Burg G: CD44v6 is a marker for systemic spread in cutaneous T cell lymphomas: a comparative study between nodal and cutaneous lymphomas. J Cutan Pathol 1995, 22:407-412.
35. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, Gunthert U: Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 1996, 148:453-463.
36. Kan M, Akiyama K, Naruo S, Kanayama H, Kagowa S: High level expression of the CD44 variant sharing exon v10 in renal cancer. Jpn J Cancer Res 1995, 86:847-853.
37. Friedrichs F, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ, Holzel F, Maass H, Gunthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995, 55:5424-5433.
38. Sinn HP, Heider KH, Skroch-Angel P, von-Minckwitz G, Kaufmann M: Human mammary carcinomas express homologous of rat metastasis associated variants of CD44. Breast Cancer Res Treat 1995, 36:307-313.
39. Kainz C, Kohlberger P, Tempter C, Sliutz G, Gitsch G, Reinthaller A: Prognostic value of CD44 splice vairants in human stage III cervical cancer. Eur J Cancer 31A:1709-1709.
40. Ghaffari S, Dougherty GJ, Lansdorp PM, Raves AC, Eaves CJ: Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia. Blood 1995, 86:2976-2985.
41. Gansauge F, Gansuage S, Zobywalski A, Scharnweber C, Link LK, Nussler AK: Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res 1995, 55:5499-5503.
42. Shtivelman E, Bishop MJ: Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991, 11:5446-5453.
43. Cannistra S, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C: Binding of ovarian cancer cells to peritoneal medothelium in vitro is partly mediated by CD44H. Cancer Res 1993, 53:3830-3838.
44. Salmi M, Gron-Virta K, Sointu P, Grenman R, Kalimo H, Jalkannen S: Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993, 122:431-442.
45. Ariza A, Mate JL, Isamat M, Loper D, von-Unexkull-Guldeband C, Rosell R: Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. J Pathol 1995, 177:363-368.
46. Nagabhushan M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP, Sy MS: Altered expression of CD44 in prostate cancer metastases. J Clin Pathol 1996, in press.
47. Takahashi K, Stamenkovic I, Cutler M, Saya H, Tanabe KK: CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogens 1995, 11:2223-2232.
48. Combaret V, Gross N, Frappaz D, Peruisseau G, Philip T, Beck D: Clinical relevance of CD44 cell surface expression and n-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1995, 14:25-34.
49. Combaret V, Lasset C, Frappaz D, Bouvier R, Thiesse P, Rebillard AC: Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Eur J Cancer 1995, 31A:545-549.
50. Terpe HJ, Christiansen H, Gonzalez M, Berthold F, Lampert F: Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44S. Eur J Cancer 1995, 31A:549-552.
51. Gross N, Mech D, Beretta C, Jackson D, Perruisseau G: CD44 expression and modulation on human neuroblastoma tumors and cell lines. Eur J Cancer 1995, 31A:471-475.
52. Christiansen H, Sahin K, Berthold F, Hero B, Terpe HJ, Lampert F: Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 1995, 31A:541-544.
53. Guo YJ, Liu GG, Wang XN, Jin D, Wu MC, Ma J, Sy SM: Soluble CD44 in the serum as an indicator of tumor growth and metastasis in patients with gastric or colon cancer. Cancer Res 1994, 54:422-426.
54. Ristamaki R, Joensuu H, Jalkanen S: Does soluble CD44 reflect the clinical behavior of human cancer. In Attempts to Understand Metastasis formation III. Edited by Gunthert U, Schlag PM, Birchmeier W. Current Topics in Microbiology and Immunology. 213/III, 155-166. Berlin:Springer-Verlag.
55. Sliutz G, Temfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C: Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 1995, 72:1494-1497.
56. Matsumura Y, Sugiyama M, Matsumura S, Hayle AJ, Robinson P, Smith JC, Tarin D: Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 1995, 177:11-20.
57. Ermak G, Jennings T, Bouguniewicz A, Figge J: Novel CD44 mRNA isoforms in human thyroid and breast tissues feature unusual sequence rearrangements. Clin Cancer Res 1996, 2:1251-1254.